Search results for " Modality"

showing 10 items of 461 documents

Urrets-Zavalia Syndrome After Combined Trabeculotomy-Trabeculectomy Surgery

2018

We report a case of a rare complication after trabeculotomy combined with a small trabeculectomy with mitomycin C in a young patient with juvenile glaucoma. The patient underwent uneventful surgery. However, postoperatively, he experienced a long-lasting hypotony with the need of 2 revision surgeries and 2 short episodes of high-intraocular pressure. He developed a fixed dilated pupil over time.

AdultMalemedicine.medical_specialtyJuvenile glaucomaMitomycinmedicine.medical_treatmentGlaucomaTrabeculectomy03 medical and health sciencesPostoperative Complications0302 clinical medicinePupil DisordersmedicineHumansTrabeculectomyIntraocular Pressurebusiness.industryMitomycin CHydrophthalmosGlaucomaSyndromeUrrets Zavalia syndromemedicine.diseaseCombined Modality TherapyTrabeculotomySurgeryOphthalmology030221 ophthalmology & optometryComplicationbusiness030217 neurology & neurosurgeryJournal of Glaucoma
researchProduct

Adhesive Small Bowel Obstruction: Predictive Factors of Lack of Response in Conservative Management with Gastrografin

2015

<b><i>Background:</i></b> Gastrografin represents a useful tool in the diagnosis and management of adhesive small bowel obstruction (ASBO). The aim of this study is to identify variables with negative influence in nonoperative management with gastrografin. <b><i>Methods:</i></b> From August 2008 to March 2013, 223 consecutive patients with 235 episodes of ASBO were included and received gastrografin. A protocol for prospective data collection was developed. In order to explore factors related to the failure of nonoperative treatment, univariate and multivariate analysis were performed. <b><i>Results:</i></b> One hundred…

AdultMalemedicine.medical_specialtyMultivariate analysisConservative managementClinical Decision-MakingGastrografinContrast MediaProspective dataTissue Adhesions030230 surgery03 medical and health sciencesPostoperative Complications0302 clinical medicineIntestine SmallmedicineHumansProspective StudiesAdhesive small bowel obstructionProspective cohort studyAgedDiatrizoate MeglumineAged 80 and overbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryRadiographyBowel obstructionClinical trialTreatment Outcome030220 oncology & carcinogenesisCohortFemaleSurgerybusinessAdhesive syndromeIntestinal ObstructionPredictive factorsAbdominal surgery
researchProduct

Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma

2013

Objective To study the effect of smoking status at diagnosis on recurrence in intermediate-risk non–muscle-invasive bladder carcinoma treated by transurethral resection (TUR) of the bladder and early intravesical chemotherapy. Methods Tumor characteristics and smoking status were recorded in 395 patients entered in a randomized multicenter trial comparing 2 different schedules of early intravesical chemotherapy. All patients received intravesical epirubicin (80 mg/50 mL) within 6 hours after TUR, followed by 5 more weekly instillations with (arm B) or without (arm A) monthly instillations for 1 year. Smoking habit was investigated at diagnosis through a structured questionnaire. Multivariat…

AdultMalemedicine.medical_specialtyMultivariate analysisTime Factorsintravesical chemotherapy non-muscle invasive bladder cancerUrologymedicine.medical_treatmentcigarette smokingKaplan-Meier EstimateCystectomyGastroenterologyDisease-Free SurvivalSettore MED/24 - UrologiaCystectomyCigarette smokingRisk FactorsMulticenter trialInternal medicinemedicineCarcinomaHumansAgedEpirubicinProportional Hazards ModelsAged 80 and overAntibiotics AntineoplasticProportional hazards modelbusiness.industryCarcinomaSmokingMiddle AgedFormer Smokermedicine.diseaseintermediate-risk tumorrecurrence.Combined Modality TherapySurgeryUrinary Bladder NeoplasmsMultivariate AnalysisFemaleNeoplasm Recurrence LocalbusinessEpirubicinmedicine.drug
researchProduct

Mature Survival Data for 176 Patients Younger Than 60 Years With Primary Myelofibrosis Diagnosed Between 1976 and 2005: Evidence for Survival Gains i…

2009

In the past 20 years, management of primary myelofibrosis (PMF) has incorporated new treatment approaches, but survival benefits have not been confirmed in controlled studies. This retrospective study includes 176 consecutive patients younger than age 60 years in whom PMF was diagnosed during a 30-year period (1976-2005). Median age at diagnosis was 50 years (range, 18-59 years), and 98 patients (55%) were men. At the time of this report, 99 patients (56%) had died; the 77 surviving patients were followed up for a median of 8 years (range, 4-24 years). Overall median survival was 9.2 years, and 15- and 20-year survival rates were 32% and 20%, respectively. According to the Dupriez Prognosti…

AdultMalemedicine.medical_specialtyMultivariate analysisTransplantation ConditioningAdolescentmedicine.medical_treatmentDiseaseHematopoietic stem cell transplantationKaplan-Meier EstimateDisease-Free SurvivalSettore MED/15 - Malattie Del Sanguemyelofibrosis survivalSurvival dataInternal medicinemedicineHumansMyelofibrosisSurvival rateProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelBrief ReportHematopoietic Stem Cell TransplantationRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyUnited StatesSurgerySurvival RatePrimary MyelofibrosisMultivariate AnalysisFemalebusiness
researchProduct

High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdraw…

2013

Few data exist on using thyrotropin alfa (recombinant human thyroid-stimulating hormone [rhTSH]) with radioiodine for thyroid remnant ablation of patients who have T4 primary tumors (invasion beyond the thyroid capsule).A retrospective chart review protocol at nine centers in Europe was set up with special waiver of need for informed consent, along with a careful procedure to avoid selection bias when enrolling patients into the database. Data on 144 eligible patients with T4 tumors were collected (T4, N0-1, M0-1; mean age 49.7 years; 65% female; 88% papillary cancer). All had received (131)I remnant ablation following TSH stimulation with rhTSH or thyroid hormone withdrawal (THW) since Jan…

AdultMalemedicine.medical_specialtyNeoplasm ResidualEndocrinology Diabetes and Metabolismmedicine.medical_treatmentUrologyRemnant ablationIodine RadioisotopesYoung AdultEndocrinologyClinical endpointmedicineHumansThyroid NeoplasmsThyrotropin AlfaThyroid cancerAgedRetrospective StudiesAged 80 and overHigh risk patientsbusiness.industryThyroidCancerMiddle Agedmedicine.diseaseAblationCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureThyroidectomyFemalebusinessHormoneThyroid
researchProduct

Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patie…

1998

Extensive pretreatment has been identified as a significant risk factor for failure of sufficient PBSC mobilization. From published data and our own experience we defined pretreatment variables which render patients at risk for not collecting at least 2.5 x 10(6) CD34-positive cells per kg bodyweight (BW). These variables were previous unsuccessful PBSC mobilization trial, previous large field radiotherapy, four or more cycles of myelosuppressive chemotherapy regimens, and combinations of extended field radiotherapy plus chemotherapy. Based on these inclusion criteria we treated 19 patients with disease-specific conventional-dose chemotherapy followed by sequential subcutaneous administrati…

AdultMalemedicine.medical_specialtyNeutropeniaFevermedicine.medical_treatmentPainSalvage therapyGastroenterologyTesticular NeoplasmsRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansMultiple myelomaTesticular cancerSalvage TherapyTransplantationMyelosuppressive ChemotherapyChemotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationDrug SynergismHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyHematopoietic Stem Cell MobilizationBlood Cell CountSeminomaSurgeryGranulocyte colony-stimulating factorLymphomaRegimenHematologic NeoplasmsFemaleInterleukin-3GerminomabusinessBone Marrow Transplantation
researchProduct

Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.

2019

Key Points Question What are the long-term results of multimodal treatment for adult attention-deficit/hyperactivity disorder (ADHD) when comparing cognitive behavioral group psychotherapy (GPT) with individual clinical management (CM) in combination with either methylphenidate or placebo? Findings In this follow-up assessment of the Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS), a multicenter randomized clinical trial, 256 adults participated in follow-up 1.5 years after the intervention ended. The severity of ADHD symptoms improved in all 4 prior treatment groups, with no significant difference found between GPT and CM, but methylphenidate was associated wit…

AdultMalemedicine.medical_specialtyRandomizationMedizinPlacebolaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawRating scalemental disordersmedicineAttention deficit hyperactivity disorderHumansYoung adultOriginal InvestigationPsychiatryCognitive Behavioral Therapybusiness.industryResearchBeck Depression InventoryGeneral MedicineMiddle Aged16. Peace & justicemedicine.diseaseCombined Modality Therapy030227 psychiatry3. Good healthOnline OnlyTreatment OutcomeAttention Deficit Disorder with HyperactivityPhysical therapyClinical Global ImpressionMethylphenidateCentral Nervous System StimulantsFemalebusiness030217 neurology & neurosurgeryFollow-Up StudiesJAMA network open
researchProduct

Deterioration in quality of life (QOL) in patients with malignant ascites : Results from a phase II/III study comparing paracentesis plus catumaxomab…

2012

Background: Malignant ascites (MA) is associated with poor prognosis and limited palliative therapeutic options. Therefore, quality of life (QoL) assessment is of particular importance to demonstrate new treatment value. Following the demonstration of the superiority of catumaxomab and paracentesis over paracentesis on puncture-free survival, this analysis aimed at comparing deterioration in QoL between both the treatment options. Patients and methods: In a randomised, multicentre, phase II/III study of patients with MA due to epithelial cell adhesion molecule (EpCAM) positive cancer, the QoL was evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life …

AdultMalemedicine.medical_specialtyRandomizationPalliative careCatumaxomabMedizinlaw.inventionYoung AdultQuality of lifeRandomized controlled triallawAntigens NeoplasmNeoplasmsAscitesAntibodies BispecificmedicineParacentesisHumansParacentesisdeteriorationAgedProportional Hazards ModelsAged 80 and overOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryAscitesmalignant ascitesHematologyOriginal ArticlesMiddle AgedEpithelial Cell Adhesion MoleculeCombined Modality TherapyhumanitiesSurgeryClinical trialOncologyquality of lifeQuality of Life and Supportive CareFemalemedicine.symptombusinessCell Adhesion Moleculesmedicine.drug
researchProduct

Photochemotherapy Alone or Combined with Interferon Alpha-2a in the Treatment of Cutaneous T-Cell Lymphoma

1990

Eighty-two patients with either mycosis fungoides (MF) or parapsoriasis en plaques were treated with psoralens ultraviolet A light (PUVA). Clinical and histologic parameters were followed for a period from 6 months to 10 years. Complete clinical clearing of lesions was observed in 51 patients (62%) and most of them were in limited-plaque MF group or parapsoriasis en plaque. The mean total dose of PUVA for complete clearing was less for early MF. Thirty-one patients (38%) relapsed and responded to additional PUVA. Patients in early stages of the disease remained clear for up to 68 months after the first course of PUVA. Post-treatment skin biopsies with early MF showed histologic clearing. A …

AdultMalemedicine.medical_specialtySkin NeoplasmsCombination therapyConstitutional symptomsDermatologyInterferon alpha-2BiochemistryMycosis FungoidesInterferonmedicineHumansSezary SyndromePUVA TherapyMolecular BiologyDepression (differential diagnoses)AgedNeoplasm StagingMycosis fungoidesParapsoriasisbusiness.industryCutaneous T-cell lymphomaInterferon-alphaCell BiologyMiddle Agedmedicine.diseaseCombined Modality TherapyDermatologyRecombinant ProteinsLymphoma T-Cell CutaneousDrug EvaluationFemalebusinessProgressive diseasemedicine.drugJournal of Investigative Dermatology
researchProduct

Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression

2009

Abstract Background There is substantial evidence that early improvement (EI) under antidepressant treatment is a clinically useful predictor of later treatment outcome in patients with major depressive disorders. The aim of this study was to test whether EI can also be used as a predictor for treatment outcome in patients with mild major, minor or subsyndromal depression, i.e. patients, who are typically treated by general practitioners. Methods Analyses were carried out using data from 223 patients of a 10-weeks randomized, placebo-controlled trial comparing the effectiveness of sertraline and cognitive-behavioural therapy (CBT) in patients with mild major, minor or subsyndromal depressio…

AdultMalemedicine.medical_specialtyTime FactorsSeverity of Illness Indexlaw.inventionRandomized controlled trialPredictive Value of TestslawSertralineSurveys and QuestionnairesInternal medicineSeverity of illnessmedicineHumansProspective StudiesPsychiatryProspective cohort studyDepression (differential diagnoses)Depressive DisorderDepressive Disorder MajorSertralineCognitive Behavioral TherapyHamilton Rating Scale for DepressionCombined Modality TherapyAntidepressive AgentsConfidence intervalPsychiatry and Mental healthClinical PsychologyTreatment OutcomePredictive value of testsFemalePsychologymedicine.drugJournal of Affective Disorders
researchProduct